American Century Companies Inc. Buys 957,842 Shares of Phreesia, Inc. $PHR

Key Points

• American Century Companies Inc. significantly increased its stake in Phreesia, Inc. by 3,741.9% in the first quarter, owning approximately 1.67% of the company, worth $25.1 million.
• Insiders at Phreesia sold 53,882 shares worth over $1.5 million in the last quarter, with one director decreasing their position by 4.94%.
• Phreesia has received positive ratings from analysts, with an average target price of $32.27 and most recent quarterly earnings beating estimates with a revenue increase of 14.5% year-over-year.

American Century Companies Inc. lifted its stake in shares of Phreesia, Inc. (NYSE:PHR - Free Report) by 3,741.9% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 983,440 shares of the company's stock after acquiring an additional 957,842 shares during the quarter. American Century Companies Inc. owned about 1.67% of Phreesia worth $25,137,000 as of its most recent filing with the SEC.

Other large investors also recently made changes to their positions in the company. Principal Financial Group Inc. bought a new stake in shares of Phreesia during the 1st quarter worth about $1,623,000. Deutsche Bank AG boosted its stake in Phreesia by 95.9% during the 4th quarter. Deutsche Bank AG now owns 57,297 shares of the company's stock valued at $1,442,000 after purchasing an additional 28,047 shares during the period. Bessemer Group Inc. boosted its stake in Phreesia by 23.2% during the 1st quarter. Bessemer Group Inc. now owns 47,758 shares of the company's stock valued at $1,222,000 after purchasing an additional 8,978 shares during the period. SG Americas Securities LLC bought a new stake in Phreesia during the 1st quarter valued at approximately $462,000. Finally, CWM LLC boosted its stake in Phreesia by 994.9% during the 1st quarter. CWM LLC now owns 4,040 shares of the company's stock valued at $103,000 after purchasing an additional 3,671 shares during the period. Institutional investors own 92.10% of the company's stock.

Analyst Ratings Changes

Several analysts recently weighed in on the company. Canaccord Genuity Group decreased their target price on Phreesia from $35.00 to $34.00 and set a "buy" rating for the company in a research note on Thursday, May 29th. Truist Financial upped their price objective on shares of Phreesia from $34.00 to $35.00 and gave the company a "buy" rating in a research report on Thursday, May 29th. Citigroup reissued a "buy" rating on shares of Phreesia in a research report on Wednesday, May 28th. KeyCorp upped their price target on Phreesia from $28.00 to $35.00 and gave the company an "overweight" rating in a report on Monday, July 14th. Finally, Wall Street Zen raised Phreesia from a "hold" rating to a "buy" rating in a report on Sunday, June 1st. One equities research analyst has rated the stock with a Strong Buy rating and ten have assigned a Buy rating to the stock. According to data from MarketBeat.com, Phreesia presently has an average rating of "Buy" and a consensus target price of $32.27.

Phreesia Price Performance

Shares of PHR stock traded up $0.61 during trading hours on Monday, hitting $30.36. The company had a trading volume of 1,048,008 shares, compared to its average volume of 593,822. Phreesia, Inc. has a 12 month low of $17.07 and a 12 month high of $31.04. The company has a debt-to-equity ratio of 0.02, a quick ratio of 1.95 and a current ratio of 1.95. The firm's fifty day moving average is $27.49 and its 200 day moving average is $26.39. The firm has a market capitalization of $1.81 billion, a price-to-earnings ratio of -41.03 and a beta of 0.71.

Phreesia (NYSE:PHR - Get Free Report) last issued its earnings results on Wednesday, May 28th. The company reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.13) by $0.06. The company had revenue of $115.94 million for the quarter, compared to the consensus estimate of $115.00 million. Phreesia had a negative net margin of 9.83% and a negative return on equity of 16.23%. The firm's revenue for the quarter was up 14.5% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.05) EPS. Phreesia has set its FY 2026 guidance at EPS. On average, sell-side analysts predict that Phreesia, Inc. will post -1.1 EPS for the current fiscal year.

Insider Activity

In related news, General Counsel Allison C. Hoffman sold 1,245 shares of the firm's stock in a transaction on Thursday, July 17th. The stock was sold at an average price of $26.89, for a total transaction of $33,478.05. Following the completion of the sale, the general counsel directly owned 136,978 shares of the company's stock, valued at $3,683,338.42. This trade represents a 0.90% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, COO Evan Roberts sold 1,892 shares of the firm's stock in a transaction on Thursday, July 17th. The shares were sold at an average price of $26.89, for a total value of $50,875.88. Following the sale, the chief operating officer directly owned 772,915 shares of the company's stock, valued at $20,783,684.35. This represents a 0.24% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 53,882 shares of company stock worth $1,513,007. 5.50% of the stock is currently owned by insiders.

Phreesia Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.